RecruitingPhase 2NCT07209462

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Mirum Pharmaceuticals, Inc.
Intervention: Low dose of MRM-3379(drug)
Enrollment: 60 enrolled
Eligibility: 13-45 years · MALE
Timeline: 2025 – 2027

Study locations (15)

Southwest Autism Research & Resource Center, Phoenix, Arizona, United States
Amnova Clinical Research, LLC, Irvine, California, United States
Children's Hospital of Orange County - Pediatric Subspecialty, Orange, California, United States
Uc Davis Mind Institute, Sacramento, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Neurology, Miami, Florida, United States
Emory University - The Emory Clinic - Clifton Road, Atlanta, Georgia, United States
Rush University Medical Center-Clinical Operation, Chicago, Illinois, United States
Kennedy Krieger Institute, John Hopkins School of Medicine, Baltimore, Maryland, United States
Boston Children's Hospital, Boston, Massachusetts, United States
UMass Memorial Health, Worcester, Massachusetts, United States
University of Minnesota Department of Medicine, Minneapolis, Minnesota, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Suburban Research Associates, Media, Pennsylvania, United States
Intermountain Healthcare - Park City Specialty Clinic, Salt Lake City, Utah, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07209462 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome →

← Back to all trials